Currax Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsCurrax Pharmaceuticals

Currax Pharmaceuticals

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Onzetra	Sumatriptan	2016-01-27	2024-2036	Migraine disorders , Cluster headache , Juvenile arthritis , Ankylosing spondylitis , Rheumatoid arthritis , Headache , Fever , Inflammation , Osteoarthritis , Bursitis , Back pain , Common cold , Toothache , Dysmenorrhea , Gout
Silenor	Doxepin	2010-03-17	2027-2030	Atopic dermatitis , Pruritus , Pain , Anxiety disorders , Psychotic affective disorders , Depressive disorder
Treximet	Naproxen, Sumatriptan	2008-04-15	2025-2026	Juvenile arthritis , Ankylosing spondylitis , Rheumatoid arthritis , Headache , Fever , Inflammation , Osteoarthritis , Bursitis , Back pain , Common cold , Toothache , Dysmenorrhea , Gout , Gastroesophageal reflux , Helicobacter infections , Duodenal ulcer , Zollinger-ellison syndrome , Esophagitis , Heartburn , Nausea , Sleep initiation and maintenance disorders , Allergic rhinitis perennial , Urticaria , Motion sickness , Sneezing , Anxiety disorders , Sinusitis , Asthma , Stomach ulcer , Migraine disorders , Cluster headache , Whooping cough , Bronchitis , Cough , Pharyngitis , Laryngitis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

knee osteoarthritis

,

hip osteoarthritis

,

,

,

migraine disorders

parkinson disease

,

,

breast neoplasms

,

,

radiodermatitis

,

,

non-small-cell lung carcinoma

,

thyroid neoplasms

,

esophageal neoplasms

,

,

,

,

second primary neoplasms

,

small cell lung carcinoma

,

,

,

thymus neoplasms

,

laryngeal neoplasms

,

hypopharyngeal neoplasms

,

irritable bowel syndrome

,

,

psychophysiologic disorders

,

somatoform disorders

,

,

,

,

,

anxiety disorders

,

head and neck neoplasms

,

,

,

,

sleep initiation and maintenance disorders

,

,

,

treatment-resistant depressive disorder

,

major depressive disorder

,

depressive disorder

,

,

,

healthy volunteers/patients

,

drug-related side effects and adverse reactions

,

drug interactions

,

bipolar disorder

,

gastrointestinal diseases

,

,

digestive system diseases

,

nasopharyngeal carcinoma

,

breakthrough pain

,

disseminated intravascular coagulation

,

venous thromboembolism

,

thromboembolism

,

Histone-arginine methyltransferase carm1

hypopituitarism

,

neurogenic diabetes insipidus

,

,

anxiety disorders

parkinson disease

,

,

breast neoplasms

,

,

radiodermatitis

,

,

non-small-cell lung carcinoma

,

thyroid neoplasms

,

esophageal neoplasms

,

,

,

,

second primary neoplasms

,

small cell lung carcinoma

,

,

,

thymus neoplasms

,

laryngeal neoplasms

,

hypopharyngeal neoplasms

,

irritable bowel syndrome

,

,

psychophysiologic disorders

,

somatoform disorders

,

,

,

,

,

anxiety disorders

,

head and neck neoplasms

,

,

,

,

sleep initiation and maintenance disorders

,

,

,

treatment-resistant depressive disorder

,

major depressive disorder

,

depressive disorder

,

,

,

healthy volunteers/patients

,

drug-related side effects and adverse reactions

,

drug interactions

,

bipolar disorder

,

gastrointestinal diseases

,

,

digestive system diseases

,

nasopharyngeal carcinoma

,

breakthrough pain

Lorcaserin hydrochloride anhydrous

,

small cell lung carcinoma

Lorcaserin hydrochloride hemihydrate

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use